Related Experiment Video

Updated: Jul 6, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

The Montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson's disease

David J Gill1, Arielle Freshman1, Jennifer A Blender2

  • 1Department of Neurology, University of Rochester, Rochester, NY.

Movement Disorders : Official Journal of the Movement Disorder Society
|April 3, 2008
PubMed

Insights

The Montreal Cognitive Assessment (MoCA) shows promise as a reliable and valid screening tool for detecting cognitive impairment in Parkinson

Area of Science:

  • Neurology
  • Neuropsychology
  • Gerontology

Background:

  • Cognitive impairment is a frequent and early symptom in Parkinson's disease (PD).
  • Current screening methods for mild cognitive impairment in PD are insufficient.
  • Early detection of cognitive changes is crucial for managing PD progression.

Purpose of the Study:

  • To evaluate the Montreal Cognitive Assessment (MoCA) as a screening tool for cognitive dysfunction in Parkinson's disease.
  • To determine the reliability and validity of the MoCA in a PD population.

Main Methods:

  • Assessed test-retest and interrater reliability of the MoCA.
  • Correlated MoCA scores with a comprehensive neuropsychological test battery.
  • Utilized intraclass correlation coefficients (ICCs) to measure reliability.

Main Results:

  • The MoCA demonstrated good test-retest reliability (ICC = 0.79).
  • High interrater reliability was observed (ICC = 0.81).
  • A strong correlation was found between MoCA scores and a neuropsychological battery (r = 0.72).

Conclusions:

  • The Montreal Cognitive Assessment (MoCA) is a reliable and valid tool for screening cognitive dysfunction in Parkinson's disease.
  • The MoCA warrants further investigation as a practical screening instrument for early cognitive changes in PD.
  • This study supports the use of MoCA for identifying cognitive impairment in PD patients.

More Related Videos

Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder04:33

Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder

Published on: April 26, 2024

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...